News | February 18, 2026
Scinai acquires Recipharm Israel to expand global reach
This transaction fundamentally strengthens Scinai's CDMO platform
This transaction fundamentally strengthens Scinai's CDMO platform
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
Iberdomide has the potential to be the first approved CELMoD agent
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
This achievement validates global demand and catapults Wanbury into high-growth acceleration
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
_256_384.jpg)
Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
Subscribe To Our Newsletter & Stay Updated
